Novo Nordisk Rebounds in Obesity Drug Race, Challenging Eli Lilly's Lead

Novo Nordisk is regaining ground against rival Eli Lilly in the high-stakes obesity drug market, driven by the strong performance of its oral version of Wegovy. After a difficult two-year period, the Danish pharmaceutical company's recent momentum has boosted investor confidence and intensified the rivalry for dominance in a market analysts project could be worth over $100 billion in the U.S. alone by the end of the decade.

Shifting Market Dynamics

While Eli Lilly's injectable Zepbound maintains a commanding lead over Novo's injectable Wegovy, with weekly U.S. prescriptions more than double in recent months, the battle is heating up in the oral drug segment. Recent IQVIA prescription data indicates that demand for Novo's oral Wegovy, launched in the U.S. in January, is stronger than initially anticipated and is outpacing Lilly's competing pill, Foundayo.

The positive signs have been reflected in Novo's stock, which has climbed approximately 35% from a low point in March. This follows a period of restructuring for the company, which included 9,000 job cuts and a CEO change after multiple guidance reductions in 2025.

A More Aggressive Strategy

Investors and analysts note a more assertive approach from Novo Nordisk. "Novo is a different Novo today than a year ago," said Morten Gregersen, chief portfolio manager at Novo shareholder Formuepleje, in an interview with Reuters. "They’re much more consumer-oriented and they’ve become much more aggressive."

Ad

This shift is evident in the company's recent legal actions. Last month, Novo filed a lawsuit in a U.S. federal court accusing Lilly of false advertising by using efficacy comparisons that omit Novo's newer, higher-dose Wegovy. BMO analyst Evan Seigerman described the move as an attempt by Novo to "make some noise" and "shift opinions," though its ultimate market impact remains uncertain.

Investor Outlook

All eyes are on the upcoming second-quarter results from both companies, scheduled for August 5. Investors will be looking for confirmation that Novo's turnaround is durable. While analysts expect robust sales from Lilly's blockbuster drugs, the focus for Novo will be on sustained growth and stable guidance.

"The real question is...when is the inflection point?" said HSBC analyst Rajesh Kumar. For many investors, a lack of negative surprises would be a welcome development. Markus Manns, a portfolio manager at Union Investment, told Reuters that even without a guidance raise, "it will be comforting to know that the company has left the era of profit warnings."